Cargando…

Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems

BACKGROUND: To evaluate the diagnostic performance of multiparametric transrectal ultrasound (TRUS) and to design diagnostic scoring systems based on four modes of TRUS to predict peripheral zone prostate cancer (PCa) and clinically significant prostate cancer (csPCa). METHODS: A development cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tong, Wang, Fei, Chen, Hanbing, Wang, Meng, Liu, Peiqing, Liu, Songtao, Zhou, Yibin, Ma, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016931/
https://www.ncbi.nlm.nih.gov/pubmed/35439952
http://dx.doi.org/10.1186/s12894-022-01013-8
_version_ 1784688660734541824
author Chen, Tong
Wang, Fei
Chen, Hanbing
Wang, Meng
Liu, Peiqing
Liu, Songtao
Zhou, Yibin
Ma, Qi
author_facet Chen, Tong
Wang, Fei
Chen, Hanbing
Wang, Meng
Liu, Peiqing
Liu, Songtao
Zhou, Yibin
Ma, Qi
author_sort Chen, Tong
collection PubMed
description BACKGROUND: To evaluate the diagnostic performance of multiparametric transrectal ultrasound (TRUS) and to design diagnostic scoring systems based on four modes of TRUS to predict peripheral zone prostate cancer (PCa) and clinically significant prostate cancer (csPCa). METHODS: A development cohort involved 124 nodules from 116 patients, and a validation cohort involved 72 nodules from 67 patients. Predictors for PCa and csPCa were extracted to construct PCa and csPCa models based on regression analysis of the development cohort. An external validation was performed to assess the performance of models using area under the curve (AUC). Then, PCa and csPCa diagnostic scoring systems were established to predict PCa and csPCa. The diagnostic accuracy was compared between PCa and csPCa scores and PI-RADS V2, using receiver operating characteristics (ROC) and decision curve analysis (DCA). RESULTS: Regression models were established as follows: PCa = − 8.284 + 4.674 × Margin + 1.707 × Adler grade + 3.072 × Enhancement patterns + 2.544 × SR; csPCa = − 7.201 + 2.680 × Margin + 2.583 × Enhancement patterns + 2.194 × SR. The PCa score ranged from 0 to 6 points, and the csPCa score ranged from 0 to 3 points. A PCa score of 5 or higher and a csPCa score of 3 had the greatest diagnostic performance. In the validation cohort, the AUC for the PCa score and PI-RADS V2 in diagnosing PCa were 0.879 (95% confidence interval [CI] 0.790–0.967) and 0.873 (95%CI 0.778–0.969). For the diagnosis of csPCa, the AUC for the csPCa score and PI-RADS V2 were 0.806 (95%CI 0.700–0.912) and 0.829 (95%CI 0.727–0.931). CONCLUSIONS: The multiparametric TRUS diagnostic scoring systems permitted better identifications of peripheral zone PCa and csPCa, and their performances were comparable to that of PI-RADS V2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-022-01013-8.
format Online
Article
Text
id pubmed-9016931
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90169312022-04-20 Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems Chen, Tong Wang, Fei Chen, Hanbing Wang, Meng Liu, Peiqing Liu, Songtao Zhou, Yibin Ma, Qi BMC Urol Research BACKGROUND: To evaluate the diagnostic performance of multiparametric transrectal ultrasound (TRUS) and to design diagnostic scoring systems based on four modes of TRUS to predict peripheral zone prostate cancer (PCa) and clinically significant prostate cancer (csPCa). METHODS: A development cohort involved 124 nodules from 116 patients, and a validation cohort involved 72 nodules from 67 patients. Predictors for PCa and csPCa were extracted to construct PCa and csPCa models based on regression analysis of the development cohort. An external validation was performed to assess the performance of models using area under the curve (AUC). Then, PCa and csPCa diagnostic scoring systems were established to predict PCa and csPCa. The diagnostic accuracy was compared between PCa and csPCa scores and PI-RADS V2, using receiver operating characteristics (ROC) and decision curve analysis (DCA). RESULTS: Regression models were established as follows: PCa = − 8.284 + 4.674 × Margin + 1.707 × Adler grade + 3.072 × Enhancement patterns + 2.544 × SR; csPCa = − 7.201 + 2.680 × Margin + 2.583 × Enhancement patterns + 2.194 × SR. The PCa score ranged from 0 to 6 points, and the csPCa score ranged from 0 to 3 points. A PCa score of 5 or higher and a csPCa score of 3 had the greatest diagnostic performance. In the validation cohort, the AUC for the PCa score and PI-RADS V2 in diagnosing PCa were 0.879 (95% confidence interval [CI] 0.790–0.967) and 0.873 (95%CI 0.778–0.969). For the diagnosis of csPCa, the AUC for the csPCa score and PI-RADS V2 were 0.806 (95%CI 0.700–0.912) and 0.829 (95%CI 0.727–0.931). CONCLUSIONS: The multiparametric TRUS diagnostic scoring systems permitted better identifications of peripheral zone PCa and csPCa, and their performances were comparable to that of PI-RADS V2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-022-01013-8. BioMed Central 2022-04-19 /pmc/articles/PMC9016931/ /pubmed/35439952 http://dx.doi.org/10.1186/s12894-022-01013-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Tong
Wang, Fei
Chen, Hanbing
Wang, Meng
Liu, Peiqing
Liu, Songtao
Zhou, Yibin
Ma, Qi
Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title_full Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title_fullStr Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title_full_unstemmed Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title_short Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
title_sort multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016931/
https://www.ncbi.nlm.nih.gov/pubmed/35439952
http://dx.doi.org/10.1186/s12894-022-01013-8
work_keys_str_mv AT chentong multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT wangfei multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT chenhanbing multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT wangmeng multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT liupeiqing multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT liusongtao multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT zhouyibin multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems
AT maqi multiparametrictransrectalultrasoundforthediagnosisofperipheralzoneprostatecancerandclinicallysignificantprostatecancernovelscoringsystems